Because stand-alone pharmacokinetic (PK) studies are usually designed to focus on intrinsic and extrinsic factors that have a high potential to affect drug exposure, they leave other possible interactions unstudied; population PK (popPK) analysis allows for an assessment of multiple factors that are not otherwise evaluated in healthy volunteers and allows for a larger number of individuals to be included.
HLX01, a biosimilar rituximab approved by China’s National Medicinal Products Administration in February of this year, is China’s first biosimilar product to be approved under national guidelines that were set forth in 2015. The biosimilar was approved to treat lymphoma, and it was simultaneously developed as a novel product for the treatment of rheumatoid arthritis (RA), as the reference rituximab was not approved to treat RA in China, so no extrapolation for the indication could be granted.
The biosimilar is currently in phase 3 clinical development for RA, and during the European Society for Medical Oncology Asia Congress 2019, held last week in Singapore, researchers reported on their development of a population (pop) pharmacokinetic (PK) model that used PK data from the biosimilar and its reference in patients with RA and employed validation from patients with diffuse large B-cell lymphoma (DLBCL).
Because stand-alone PK studies are usually designed to focus on intrinsic and extrinsic factors that have a high potential to affect drug exposure, they leave other possible interactions unstudied; popPK analysis allows for an assessment of multiple factors that are not otherwise evaluated in healthy volunteers and allows for a larger number of individuals to be included.
The popPK model of the biosimilar and the EU-licensed reference from the study in 196 patients with RA had a serum sample number of 4289. It was developed with a nonlinear mixed-effect modeling using a first-order estimation with interaction method. PK and pharmacodynamic relationships were characterized using covariates including demographics and medical history, and these were examined using forward addition and backward elimination. The final model was validated using PK samples from the biosimilar and China-licensed reference rituximab from a study in 110 patients with DLBCL.
Using the model, the estimated clearance (CL), central volume (Vc), peripheral compartment volume, and clearance-of-distribution from the central to the peripheral compartment were 27.32%, 16.56%, 21.61%, and 40.79%, respectively. Correlation between CL and Vc was 0.02239.
The observed concentrations and simulations-based 95% CIs for the corresponding model successfully predicted all subjects in the data set, demonstrating PK similarity of the biosimilar and the reference in patients with RA and DLBCL, and no significant difference in area under the curve from zero to infinity was observed between the products.
According to the authors, the results of the model provide further evidence of the PK similarity of the biosimilar and its reference in both patients with RA and DLBCL.
Reference
Shi Y, Quin Y, Zhao S, et al. A population pharmacokinetic model: assessment of pharmacokinetic similarity of HLX01 and rituximab in diffuse large B-cell lymphoma. Presented at: European Society for Medical Oncology Asia Congress 2019; November 22-24, 2019; Singapore.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.